Inactive Instrument

ProNAi Therapeutics Inc Nasdaq

Equities

US74346L1017

Biotechnology & Medical Research

DNAI The Law Offices of Vincent Wong Launch an Investigation of ProNAi Therapeutics Inc. for Possible Securities Fraud Violations

October 27, 2016 at 01:59 pm EDT

The Law Offices of Vincent Wong are investigating ProNAi Therapeutics Inc. (NASDAQ:DNAI) in relation to possible violations of federal securities laws by the Company and/or certain of its directors and officers.

To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/DNAI-Info-Request-Form-1368.

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20161027006532/en/

Latest news about ProNAi Therapeutics Inc

Sierra Oncology, Inc. Announces Update on Sra737	23-03-06	CI
Sareum Holdings Says GSK Completes Acquisition of Sierra Oncology	22-07-04	DJ
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from NASDAQ Composite Index	22-07-04	CI
Sierra Oncology, Inc. Announces Executive Changes	22-07-01	CI
GSK Completes $1.9 Billion Purchase of Sierra Oncology	22-07-01	MT
GlaxoSmithKline plc completed the acquisition of Sierra Oncology, Inc. from Frazier Healthcare VI, L.P., Frazier Life Sciences VIII, L.P., Frazier Life Sciences Public Fund, L.P., all managed by Frazier Management, L.L.C., and others.	22-06-30	CI
Sierra Oncology Shareholders Approve Acquisition by GSK	22-06-29	MT
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2500 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Completeness Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell 3000E Value Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000E Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell Small Cap Comp Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 2000 Dynamic Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) added to Russell 3000 Growth Index	22-06-24	CI
Sierra Oncology, Inc.(NasdaqGM:SRRA) dropped from Russell Microcap Value Index	22-06-24	CI
Sierra Oncology Submits New Drug Application to FDA for Cancer Treatment Momelotinib	22-06-17	MT
Sierra Oncology, Inc. Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration	22-06-17	CI
Pfizer to sell stake in GSK's consumer health business after it lists	22-06-01	RE
GSK to spend up to $3.3 bln on Affinivax to boost vaccines roster	22-05-31	RE
Sierra Oncology, Inc. Announces Momelotinib Pivotal Phase 3 Data Receives Oral Presentation At American Society of Clinical Oncology Annual Meeting	22-05-26	CI

Chart ProNAi Therapeutics Inc

Duration

Period

More charts

Company Profile

Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company's lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	105B
REGENERON PHARMACEUTICALS, INC.	+3.31%	97.5B
ARGENX SE	+1.66%	22.19B
BIONTECH SE	-16.16%	21.33B
GENMAB A/S	-6.82%	18.68B
WUXI APPTEC CO., LTD.	-41.41%	16.6B
BEIGENE, LTD.	-22.87%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	14.09B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.99B

Bio Therapeutic Drugs